S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway
Kinnari Sathe(University of Aberdeen), Peter Teismann, Matthis Synofzik(German Center for Neurodegenerative Diseases), Shigeyoshi Itohara(RIKEN Center for Brain Science), Heather L. Martin(Translational Therapeutics (United States)), Sarah Mustafa(University of Aberdeen), Walter Maetzler(Christian-Albrechts-Universität zu Kiel), Claudia Schulte(School of the Art Institute of Chicago), Zvonimir Vukovic, Johannes Lang(German Center for Neurodegenerative Diseases), Daniela Berg(Christian-Albrechts-Universität zu Kiel), Corina Fleckenstein, Ross B. Mounsey(University of Aberdeen)
Cited by 204
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846